References
- Valizadeh H, Farajni A, Zakeri-Milani P. Formulation of cefuroxime axetil oral suspension and investigation of its pharmaceutical properties. Adv Pharmaceut Bull 2011;1:93–96
- Knapp CC, Washington JA. In vitro activities of LY163892, cefaclor, and cefuroxime. Antimicrob Agents Chemother 1988;32:131–133
- Pistos C, Michaelea S, Kalovidouris M, et al. Bioequivalence evaluation of 2 brands of cefuroxime axetil 250 mg tablets in healthy human volunteers. Int J Clin Pharmacol Therapeut 2004;42:367–372
- Gleckman RA, Narayanan S. Principles of antibiotic therapy. In: Schlossberg D, ed. Current therapy of infectious disease. 2nd ed. St. Louis: Mosby; 2001:723–728
- Duncombe A, Gueudry J, Massy N, et al. Severe pseudouveitis associated with moxifloxacin therapy. J Fr Ophtalmol 2013;36:146–150
- Dcycheva D, Deuter C, Zierhut M. Therapy of intermediate uveitis. Ophthalmologe 2014;111:1219–1234
- Moorthy RS, London NJ, Garg SJ, Cunningham ET Jr. Drug-induced uveitis. Curr Opin Ophthalmol 2013;24:589–597
- Svensson CK, Cowen EW, Gaspari AA. Cutanoeous drug reactions. Pharmacol Rev 2001;53:357–379
- Segreti J, Trenholme GM, Levin S. Antibiotic therapy in the allergic patient. Med Clin North Am 1995;79:935–942
- Murat SN, Karasu BB, Ornek E, Akdemir R. Cefuroxime axetil induced allergic angina. Int J Cardiol 2011;151:53–55
- Pastuszczak M, Lipko-Godlewska S, Jaworek AK, Wojas-Pelc A. Drug-induced linear IgA bullous dermatosis after discontinuation of sefuroxime axetil treatment. J Dermatol Case Rep 2012;6:117–119